Home » Topics » BioWorld Science, Infection

BioWorld Science, Infection
RSS

Committee recommends continuation of Atox Bio's phase III ACCUTE study

Nov. 4, 2016

Intravenous zanamivir shows potential for severe influenza in pediatric patients

Nov. 4, 2016

Rebiotix's RBX-2660 effective in phase IIb trial for recurrent Clostridium difficile infection

Nov. 4, 2016

Researchers present phase II data for maribavir for treatment of cytomegalovirus infections

Nov. 4, 2016

EnBiotix acquires AMP Therapeutics' antimicrobial peptide portfolio

Nov. 3, 2016

Janssen's JNJ-53718678 safe in phase I trial for RSV

Nov. 2, 2016

SK Chemical's NBP607-QIV effective in phase III influenza study

Nov. 2, 2016

Cempra receives milestone payment from Toyama Chemical

Nov. 2, 2016

IURTC presents anti-HBV agents

Nov. 2, 2016

MSD files for approval of bezlotoxumab in Japan

Oct. 31, 2016

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 6, 2026.
CROI 2026 highlights depression and cognitive vulnerability in HIV
BioWorld
The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
University of Southern California reports new MAPT aggregation inhibitors
BioWorld Science
The University of Southern California has identified (2-oxo-2H-chromen-3-yl) scaffold-based carboxamide analogues acting as potent microtubule-associated protein...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...